Laurus Labs Ltd (LAURUSLABS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Laurus Labs Ltd (LAURUSLABS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8140
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Laurus Labs Ltd (Laurus Labs) is a drug development company that manufactures active pharmaceutical ingredients. The company develops products through its business divisions such as laurus generics, ingredients and synthesis. It offers active pharmaceutical ingredients and intermediates for anti-retroviral and Hepatitis C. Laurus Labs also provides active pharmaceutical ingredients for oncology and other therapeutic areas. The company manufactures ingredients for use in nutraceutical, dietary supplements and cosmeceutical products. It also offers drug substance, analytical development and product development services. The company operates research and development, and drug substance manufacturing facilities in Hyderabad and Visakhapatnam. Laurus Labs is headquartered in Hyderabad, Telangana, India.

Laurus Labs Ltd (LAURUSLABS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laurus Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Warburg Pincus Acquires 32.29% Stake in Laurus Labs for USD90 Million 10
Fidelity Growth Partners India Invests US$40 Million In Aptuit Laurus 12
Licensing Agreements 13
Laurus Labs Enters into Licensing Agreement with Medicines Patent Pool 13
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 14
Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 15
Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 16
Equity Offering 17
Laurus Labs Raises USD194 Million in IPO 17
Acquisition 18
Laurus Labs Acquires 27% Stake in Sriam Labs for USD1.2 Million 18
Laurus Labs Ltd – Key Competitors 19
Laurus Labs Ltd – Key Employees 20
Laurus Labs Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Joint Venture 22
Recent Developments 23
Financial Announcements 23
Nov 09, 2017: Laurus Labs Records Healthy Performance, PAT Grows at 19% in H1 FY I8 23
May 18, 2017: Laurus Labs Reports Revenue Of INR19.3 Billion In Fiscal 2018 25
Feb 09, 2017: Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO 26
Corporate Communications 27
Mar 08, 2018: Laurus Labs: Resignation of Executive Director 27
Mar 08, 2018: Laurus Labs Appoints Dr. Venkata Lakshmana Rao Chunduru as Executive Director 28
Mar 28, 2017: Laurus Labs Announces Resignation of Director 29
Jan 02, 2017: Laurus Labs: Resignation of Director 30
Legal and Regulatory 31
Mar 01, 2018: Laurus Labs Completes USFDA Inspection Of Unit 2 With No Observations- Zero 483 31
Nov 14, 2017: laurus labs recieves the EIR for its unit 1 & 3 32
Sep 15, 2017: Laurus Labs Recivces the EIR from UFDA, and also Successfully Completes of the German Regulatory Authority for Unit-2 and WHO inspections for Unit-3 API Facilities 33
Aug 18, 2017: Laurus Labs Announces Successful Completion of U.S. FDA Inspection for Unit-1 and Unit-3 API Facilities 34
May 19, 2017: Laurus Labs Announces Successful Completion of U.S. FDA Inspection 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laurus Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laurus Labs Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Warburg Pincus Acquires 32.29% Stake in Laurus Labs for USD90 Million 10
Fidelity Growth Partners India Invests US$40 Million In Aptuit Laurus 12
Laurus Labs Enters into Licensing Agreement with Medicines Patent Pool 13
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 14
Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 15
Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 16
Laurus Labs Raises USD194 Million in IPO 17
Laurus Labs Acquires 27% Stake in Sriam Labs for USD1.2 Million 18
Laurus Labs Ltd, Key Competitors 19
Laurus Labs Ltd, Key Employees 20
Laurus Labs Ltd, Other Locations 21
Laurus Labs Ltd, Subsidiaries 21
Laurus Labs Ltd, Joint Venture 22

List of Figures
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Laurus Labs Ltd (LAURUSLABS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Grupo Financiero Galicia SA (GGAL3):企業の財務・戦略的SWOT分析
    Grupo Financiero Galicia SA (GGAL3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Relation Insurance Services, Inc:企業の戦略・SWOT・財務情報
    Relation Insurance Services, Inc - Strategy, SWOT and Corporate Finance Report Summary Relation Insurance Services, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Select Medical Holdings Corp (SEM):企業の財務・戦略的SWOT分析
    Summary Select Medical Holdings Corp (Select Medical) is a healthcare service provider that offers outpatient rehabilitation services. The center provides long-term acute care services such as complex infectious disease treatment, respiratory failure, medically complex treatment, neurology, pulmonar …
  • Vocalink Limited
    Vocalink Limited - Strategy, SWOT and Corporate Finance Report Summary Vocalink Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • C&A:戦略・SWOT・企業財務分析
    C&A - Strategy, SWOT and Corporate Finance Report Summary C&A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing …
  • The Dai-ichi Life Insurance Co Ltd:戦略・SWOT・企業財務分析
    The Dai-ichi Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The Dai-ichi Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Kronos Worldwide Inc (KRO):企業の財務・戦略的SWOT分析
    Kronos Worldwide Inc (KRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Response Biomedical Corp:企業の戦略的SWOT分析
    Response Biomedical Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • ReproCELL Inc (4978):企業の財務・戦略的SWOT分析
    Summary ReproCELL Inc (ReproCELL) is a biotechnology company that develops and commercializes stem cell technologies. The company offers products in divisions such as research reagents, cultivation materials, and cell and biorepository. Its research reagent products include hES iPSC culture reagents …
  • Sky plc:企業の戦略・SWOT・財務分析
    Sky plc - Strategy, SWOT and Corporate Finance Report Summary Sky plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Cognition Financial Corporation:企業の戦略・SWOT・財務情報
    Cognition Financial Corporation - Strategy, SWOT and Corporate Finance Report Summary Cognition Financial Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Quotient Sciences Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Quotient Sciences Ltd (Quotient Sciences), formerly Pharmaceutical Profiles Group Ltd is a drug development service provider. The company offers services such as formulation development, clinical trial manufacturing, clinical pharmacology, and commercial manufacturing services. Its formulati …
  • British Columbia Investment Management Corp:企業の戦略的SWOT分析
    British Columbia Investment Management Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Tri-County Rural Electric Cooperative Inc:企業の戦略的SWOT分析
    Tri-County Rural Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Pinnacle Investment Management Group Limited (PNI):企業の財務・戦略的SWOT分析
    Pinnacle Investment Management Group Limited (PNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Sunbelt Rentals Inc:企業のM&A・事業提携・投資動向
    Sunbelt Rentals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sunbelt Rentals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Britvic Plc:企業の戦略・SWOT・財務情報
    Britvic Plc - Strategy, SWOT and Corporate Finance Report Summary Britvic Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Nippon Telegraph and Telephone Corp (9432):企業の財務・戦略的SWOT分析
    Nippon Telegraph and Telephone Corp (9432) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Intech Biopharm Ltd (6461):製薬・医療:M&Aディール及び事業提携情報
    Summary Intech Biopharm Ltd (Intech Biopharm) is a drug developing company that develops drugs for obstructive airway diseases. The company provides marketed products such as single ingredient generics such as Synvent, and Duasma, developed for asthma; and multi-ingredient generic, Synflutide, for a …
  • SonaCare Medical LLC-医療機器分野:企業M&A・提携分析
    Summary SonaCare Medical LLC (SonaCare Medical), formerly US HIFU LLC is a medical device company that manufactures minimally invasive high intensity focused ultrasound (HIFU) surgical ablation systems for urological indications. The company's products include sonablate 450 and sonatherm. It offers …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆